{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:02:10Z","timestamp":1771261330331,"version":"3.50.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,13]]},"abstract":"<jats:p>\n                    Durable glycemic control remains challenging in patients with type 2 diabetes mellitus inadequately controlled with metformin alone. Liraglutide, a glucagon-like peptide-1 receptor agonist, has been proposed as a beneficial add-on therapeutic option. This retrospective study included adults with type 2 diabetes mellitus treated between March 2021 and March 2025. Patients were divided into a combination group receiving liraglutide plus metformin and a control group receiving metformin alone. Glycemic parameters and safety outcomes were assessed at baseline and after 6 months of treatment. Statistical comparisons were conducted using Welch\n                    <jats:italic toggle=\"yes\">t<\/jats:italic>\n                    test and Chi-square or Fisher exact test. A total of 207 patients were analyzed. Compared with metformin monotherapy, combination therapy achieved greater reductions in glycated hemoglobin (\u20101.8\u2005\u00b1\u20050.9% vs \u20101.3\u2005\u00b1\u20050.8%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), fasting and postprandial plasma glucose, fasting insulin, and homeostasis model assessment of insulin resistance. The proportion achieving composite glycemic targets was higher in the combination group (76.5% vs 57.9%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.006). Adverse event incidence and treatment discontinuation did not differ significantly between groups. Liraglutide add-on therapy provided superior glycemic improvement compared with metformin alone and demonstrated acceptable safety and tolerability.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047562","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:00:14Z","timestamp":1771005614000},"page":"e47562","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative evaluation of liraglutide plus metformin combination therapy versus metformin monotherapy in patients with type 2 diabetes mellitus: A retrospective clinical study"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4123-890X","authenticated-orcid":false,"given":"Tingting","family":"Mai","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Heyuan People\u2019s Hospital, Heyuan, Guangdong Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260216","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1007\/s11845-023-03337-2","article-title":"Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis.","volume":"192","author":"Long","year":"2023","journal-title":"Ir J Med Sci"},{"key":"R2-20260216","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","article-title":"Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics.","volume":"55","author":"Jacobsen","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R3-20260216","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"key":"R4-20260216","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER.","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"R5-20260216","doi-asserted-by":"crossref","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists.","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"R6-20260216","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13300-016-0155-1","article-title":"A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus.","volume":"7","author":"Kayaniyil","year":"2016","journal-title":"Diabetes Ther"},{"key":"R7-20260216","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists.","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther"},{"key":"R8-20260216","doi-asserted-by":"crossref","first-page":"108871","DOI":"10.1016\/j.diabres.2021.108871","article-title":"Liraglutide effects on glycemic control and weight in patients with type 2 diabetes mellitus: a real-world, observational study and brief narrative review.","volume":"177","author":"Yousef","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"R9-20260216","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.pcd.2023.07.006","article-title":"Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus.","volume":"17","author":"Lee","year":"2023","journal-title":"Prim Care Diabetes"},{"key":"R10-20260216","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/medicina60030357","article-title":"A review and meta-analysis of the safety and efficacy of using glucagon-like peptide-1 receptor agonists.","volume":"60","author":"Hu","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"R11-20260216","doi-asserted-by":"crossref","first-page":"1440456","DOI":"10.3389\/fendo.2024.1440456","article-title":"A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents.","volume":"15","author":"Tegegne","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R12-20260216","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1111\/dom.16366","article-title":"The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: a systematic review and meta-analysis.","volume":"27","author":"Ren","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"R13-20260216","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"R14-20260216","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss.","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"R15-20260216","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11695-023-06484-8","article-title":"Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study.","volume":"33","author":"Jensen","year":"2023","journal-title":"Obes Surg"},{"key":"R16-20260216","first-page":"144","article-title":"Clinical efficacy and safety of liraglutide and dapagliflozin on glucose and lipid metabolism and insulin function in patients with type 2 diabetes mellitus.","volume":"30","author":"Ma","year":"2024","journal-title":"Altern Ther Health Med"},{"key":"R17-20260216","doi-asserted-by":"crossref","first-page":"1244432","DOI":"10.3389\/fendo.2023.1244432","article-title":"Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.","volume":"14","author":"Xie","year":"2023","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:01:52Z","timestamp":1771257712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047562","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"2025-11-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}